@article{d3f1a1c786014f03a4dac0286c49db7b,
title = "Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial",
abstract = "Correction to: Nature Medicinehttps://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024 In the version of the article initially published, the text “Immune-related adverse effects were exclusively associated with pembrolizumab” and, in the following sentence, also referring to adverse effects, “…all related to pembrolizumab” has been removed from the Abstract. In the final paragraph of the Results, “assessed by the treating physicians” has been inserted after “Related adverse effect to pembrolizumab…”. These changes have been made to the HTML and PDF versions of the article.",
author = "Roger Li and Shah, {Paras H.} and Stewart, {Tyler F.} and Nam, {Jong Kil} and Bivalacqua, {Trinity J.} and Lamm, {Donald L.} and Uchio, {Edward M.} and Geynisman, {Daniel M.} and Jacob, {Joseph M.} and Meeks, {Joshua J.} and Rian Dickstein and Pearce, {Shane M.} and Kang, {Seok Ho} and Jung, {Seung Il} and Kamat, {Ashish M.} and Burke, {James M.} and Keegan, {Kirk A.} and Steinberg, {Gary D.}",
note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature America, Inc. 2024.",
year = "2024",
month = jul,
doi = "10.1038/s41591-024-03137-w",
language = "English",
volume = "30",
pages = "2372",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "8",
}
